SUNSHINE PHARMA's Olaglitazar Capsules Successfully Included in the 2026 National Medical Insurance Drug Catalog

Stock News11-15

SUNSHINE PHARMA (06887) announced that its self-developed sodium-glucose transporter 2 inhibitor (SGLT-2 inhibitor) and Class 1 innovative drug, Olaglitazar Capsules (trade name: Dongzean®), has been successfully included in the latest edition of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2026) published by China's National Healthcare Security Administration. The 2026 edition of the national medical insurance drug catalog will officially take effect on January 1, 2027.

The product received marketing approval from China's National Medical Products Administration in January 2026 and can be used as monotherapy or in combination with metformin to improve blood glucose control in adult patients with type 2 diabetes mellitus (T2DM).

This product is a self-developed SGLT2 inhibitor with independent intellectual property rights. It works by strongly inhibiting renal SGLT2 to promote urinary glucose excretion and moderately inhibiting intestinal SGLT1 to reduce glucose or galactose absorption, effectively reducing severe postprandial blood glucose fluctuations and achieving "full-course, dual-channel" coordinated control of both fasting and postprandial blood glucose.

The product's registration approval was based on two multicenter, randomized, double-blind, controlled Phase III clinical studies. Both Phase III clinical studies demonstrated that Olaglitazar as monotherapy or in combination with metformin for 24 weeks significantly reduced glycated hemoglobin (HbA1c), comprehensively lowered fasting and postprandial blood glucose, and delivered multiple additional benefits including improvements in blood pressure and body weight, with efficacy maintained through 52 weeks. It demonstrated outstanding effects in improving energy metabolism, aligning with the current comprehensive management trend of "blood glucose-weight-blood pressure" in diabetes care. During clinical trials, the product showed good overall tolerability, with no significant difference in the incidence of adverse reactions compared to the placebo group.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment